Markets

Celltrion Reports Post-hoc Analysis From LIBERTY Studies

February 16, 2026 — 03:23 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Celltrion (068270.KS) announced new data from a post-hoc analysis of the LIBERTY studies, showing that subcutaneous infliximab restored and maintained response in most Crohn's disease and ulcerative colitis patients with sustained efficacy, safety, and persistence through to week 102. The company said the results demonstrated that initiation of treatment with SC infliximab 240 mg was effective to recapture and maintain disease control for Crohn's disease and ulcerative colitis patients.

Professor Stefan Schreiber, University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany, said: "This data provides evidence that subcutaneous infliximab can effectively and safely recapture disease control, offering a viable treatment option for both clinicians and patients."

At last close, Celltrion shares were trading at 2,38,500 won.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets

Latest Articles
Data is currently not available